Epithalon

Epithalon (also written as Epitalon) is a synthetic tetrapeptide designed to mimic the active fraction of epithalamin, a polypeptide extract derived from the pineal gland. Its primary mechanism of action involves the activation of telomerase, the ribonucleoprotein enzyme responsible for adding TTAGGG telomeric repeats to the 3' ends of chromosomes. Telomere shortening is a fundamental hallmark of cellular ageing; each cell division erodes telomeric DNA, and critically shortened telomeres trigger replicative senescence or apoptosis.

Epithalon induces the expression of the telomerase reverse transcriptase (hTERT) catalytic subunit, which is the rate-limiting component of telomerase assembly. By reactivating telomerase in somatic cells that have downregulated its expression, Epithalon enables telomere elongation and extends the replicative capacity of the cell beyond its normal Hayflick limit.

Beyond telomerase activation, Epithalon stimulates melatonin production from the pineal gland, helping to normalise circadian rhythm function that declines with age. It also demonstrates antioxidant properties by upregulating the expression of superoxide dismutase (SOD) and other endogenous antioxidant enzymes, reducing oxidative damage to DNA, lipids, and proteins. These combined mechanisms position Epithalon at the intersection of telomere biology, circadian regulation, and oxidative stress management.

Epithalon was developed in the 1990s by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia. Khavinson's research programme focused on short bioregulatory peptides derived from organ-specific polypeptide extracts, with the hypothesis that small peptides could reproduce the biological activity of larger glandular preparations.

Epithalamin, the pineal gland extract from which Epithalon was derived, had been studied since the 1970s for its effects on ageing and longevity. The synthetic tetrapeptide Epithalon was designed to capture the active fraction of epithalamin in a reproducible, defined molecule. Animal studies demonstrated that Epithalon increased mean and maximum lifespan in multiple species, reactivated telomerase in somatic cells, and normalised melatonin production in aged subjects. A notable longitudinal study in elderly human subjects showed that epithalamin and Epithalon administration was associated with reduced cardiovascular mortality over a 12-year follow-up period. While the research has been primarily conducted by Russian groups and requires broader independent replication, the results have generated significant interest in the ageing research community.